How to Pick the Right CDMO: The Definitive Playbook for Pharma IP Teams, Portfolio Managers, and R&D Leads
Executive Summary The global CDMO market hit USD 238.92 billion in 2024 and is on track to reach USD 465.24 […]
Strategies to Maximize Product Value Amid Loss of Exclusivity in the Pharmaceutical Industry
The Inevitable Horizon: Understanding Loss of Exclusivity (LOE) The pharmaceutical landscape is characterized by cycles of innovation, market exclusivity, and
Why Biosimilar Filings Fail: The Complete Technical Guide to 351(k) Rejections, CRL Patterns, and CMC Pitfalls
1. The Stakes: What a Failed 351(k) Filing Actually Costs A Complete Response Letter (CRL) is not an administrative inconvenience.
AI in Drug Discovery: The Complete Technical and IP Strategy Guide for Pharma Executives
1. Why Traditional Drug R&D Is Structurally Broken Between 2000 and 2015, more than 86% of drug candidates that entered
AI in Drug Discovery: The Complete Technical and IP Strategy Guide for Pharma Executives Read Post »
Authorized Generics: The Complete Data Playbook on Prevalence, Timing, and Market Impact
An authorized generic is a brand-name drug sold under a generic label. No new FDA approval required. No new manufacturing
Authorized Generics: The Complete Data Playbook on Prevalence, Timing, and Market Impact Read Post »
FDA Orange Book vs. Biologic PTAB: The Data-Driven Patent Strategy Guide Pharma Can’t Ignore
The gap between how small-molecule and biologic patents perform at the Patent Trial and Appeal Board has never been wider,
Pay-for-Delay Pharma Settlements: The Complete Antitrust & IP Strategy Guide
Pharmaceutical pay-for-delay agreements, the precise term is reverse payment patent settlements, sit at the intersection of Hatch-Waxman exclusivity mechanics, branded
Pay-for-Delay Pharma Settlements: The Complete Antitrust & IP Strategy Guide Read Post »
Authorized Generics: The Brand’s Last Weapon Against Generic Entry (And What It Costs Everyone Else)
Section 1: What an Authorized Generic Actually Is (And Why Definitions Matter for Deal Modeling) 1.1 The Core Definition An
DrugPatentWatch reveals NIH funding for patents
Here’s a summary of a new article that used DrugPatentWatch data: NIH Funding for Patents That Contribute to Market Exclusivity
DrugPatentWatch reveals NIH funding for patents Read Post »
